DPP-4抑制剂治疗新诊断Ⅱ型糖尿病的疗效观察

Therapeutic effect of Dpp-4 inhibitor on therapy in treatment of type Ⅱ diabetes

探讨DPP-4抑制剂对新诊断Ⅱ型糖尿病患者的有效性及安全性.120例新诊断Ⅱ型糖尿病患者被随机分为观察组和对照组,对照组给予二甲双胍常规治疗,观察组给予二甲双胍+二肽基肽酶-4(DPP-4)抑制剂,随访12周,观察两组空腹血糖(FPG)、餐后两小时血糖(2h PG)、Hb A1c、BMI及低血糖发生情况.12周治疗后观察组2h PG和Hb A1c相较于对照组显著下降(P<0.05),观察组Hb A1c达标率为82%,显著高于对照组的67%(P<0.05),两组治疗后BMI及低血糖发生率无显著差异(P>0.05).DPP-4抑制剂与二甲双胍联合应用治疗新诊断Ⅱ型糖尿病效果更好.

In this paper,the therapeutic effect and reliability of Dpp-4 inhibitors on therapy in the newly diagnosed T2 DM patients was investigated. 120 newly diagnosed T2 DM patients were randomized into observation group and control group. The control group was given metformin,while the observation group was given Dpp-4 inhibitors and metformin for 12 weeks. The fasting plasma glucose（FPG）, two-hour postprandial plasma glucose（2h PG）,hemoglobin A1c（Hb A1c）,body mass index（BMI） and the incidence of hypoglycemia in both groups were observed. After 12-weeks treatment,the levels of 2h PG and Hb A1 c decreased significantly in observation group compared with the control group（P 0.05）. The targeting rate of Hb A1 c in the observation group was 82% that was significantly higher than that of control group（P〈 0. 05）. The changes in BMI and the incidence of hypoglycemia of two groups were not significantly different（P〉 0. 05）. The combination of Dpp-4 inhibitors with metformin was more effective for the treatment of newly diagnosed T2 DM.